Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

CannabisNewsBreaks – Software Effective Solutions Corp. (SFWJ) to Expand Portfolio with Strategic Acquisition

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), a leading holding company in the cannabis industry, today announced final stages of negotiations to acquire its sixth cannabis company in Colombia. The acquisition is extremely significant because of the company’s cannabis genetics license, which MedCana believes will revolutionize its potential to create and register unique cannabis genetic varieties for production and commercialization. “The addition of this new company to MedCana’s portfolio represents a significant leap forward in our commitment to innovation and excellence within the cannabis sector,” said Gabriel Diaz, CEO of MedCana. “By integrating this company’s cutting-edge genetics capabilities, MedCana will be poised to develop proprietary cannabis strains, enhancing the diversity and quality of our product offerings to meet the evolving needs of consumers and medical patients alike.”

To view the full press release, visit https://cnw.fm/NKN1E

About Software Effective Solutions Corp.

Software Effective Solutions/MedCana is a holding company focused on developing companies in the agricultural technology and cannabis industries. As MedCana moves forward with its expansion plans, the company remains committed to delivering on its promise of building a solid foundation for the future growth of its holdings. For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Navy Expands Cannabis Waiver as Recruitment Nosedives

The Navy is changing its policy for recruits who test positive for cannabis upon arriving at boot camp, choosing to grant waivers rather than dismiss them outright in light of the continuous difficulties the United States military faces in recruiting. Head of the Navy’s personnel policy and plans unit, Rear Admiral James Waters, explained that if a recruit tests positive for cannabis and admits to using it, an assessment is done to make sure there are no underlying problems.

The adaptation aims to align with social laws and provide an opportunity for young people to acclimate to the Navy’s culture during boot camp. This move is a reflection of larger military attempts to solve recruitment deficiencies and lower the boot-camp dropout rate, which is currently approximately 10%, marking one of the lowest in past years.

Waters stressed that with the Navy’s target of recruiting 40,000 sailors by the end of 2024, minimizing the loss of recruits during boot camp is crucial. However, he emphasized that the more permissive attitude is limited to THC testing and doesn’t extend to other substances.

The adjustment follows a similar move by the Air Force, which saw a significant increase in enlistment waivers granted to recruits testing positive for THC than initially anticipated. General Christopher Amrhein, the Air Force’s recruitment service commander, highlighted that the waiver policy helped mitigate the impact of missing the annual recruitment goal for the first time in more than two decades.

The unit reported that it had granted 165 waivers in the first year after they were made available. That is more than three times as many waivers as it had anticipated granting each year.

The Navy and the Air Force’s recent policies represent a departure from previous strict regulations related to marijuana use, particularly in the context of CBD and hemp products. Over the years, various military units have communicated specific rules to their members regarding marijuana use, emphasizing the prohibition of hemp, CBD and marijuana products, even in states where using those substances is legal.

The Navy, for instance, prohibited the use of CBD and hemp products in 2018, with subsequent updates explaining the rationale behind the rule change. Additionally, the Naval War College issued a notice in 2022 stating that marines and sailors could test positive for cannabis if they consumed Pepsi’s Rockstar drink, which contains hemp.

Meanwhile, an Air Force base in Massachusetts issued a warning in 2021 prohibiting military personnel from even bringing hemp-infused lip balms, shampoos and lotions onto the base.

Given the rate at which more people are taking to regulated products from licensed marijuana companies such as Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), the cannabis waivers offered by the different wings of the armed forces are a rightful response to the changing public perception of this substance.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Doubles Down on GLP-1 Clinical Studies for 2024; Terms 2023 as its Most Successful and Active Year of R&D

  • Lexaria, a global innovator in drug delivery platforms to enhance bioavailability, announced recently that it will focus on GLP-1 applications for diabetes and weight loss for the 2024 calendar year
  • Chris Bunka, Lexaria’s CEO, has expressed his confidence in the company’s direction, reiterating the intention to demonstrate the superior performance of GLP-1 drugs processed with its patented DehydraTECH(TM) technology
  • The company looks to build on the success of the early-stage results achieved in 2023, and looks to embark on two human pilot studies, a multi-arm 12-week animal chronic study, a human chronic weight-loss and diabetes study, as well as a multi-month stability testing of DehydraTECH GLP-1

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced its 2024 R&D plans, with emphasis on GLP-1 investigations. GLP-1 agonists (glucagon-like peptide 1) is a class of drugs used for diabetes and weight loss.

This comes hot on the heels of a successful, active year of R&D in 2023, a year that saw significant strides in developing its patented DehydraTECH(TM) technology including its new foray into GLP-1 drugs. Chris Bunka, Lexaria’s CEO, expressed his confidence and overall optimism in the company’s new direction, reiterating the company’s intention to demonstrate the superior pharmacokinetics and safety/efficacy performance of GLP-1 drugs when formulated and processed with DehydraTECH (https://cnw.fm/5pVk5).

In 2023, DehydraTECH showed positive results in its 8-week study that involved 32 diabetic rodents. The study showed that DehydraTECH-CBD lowered triglyceride levels and body weight differential over the eight weeks, positive results that would also be replicated in its other studies including, but not limited to, hypertension, human hormones, and the overall reduced risk of oral nicotine. This laid the groundwork for Lexaria to explore a new class of molecules it had never worked on before, ultimately quietly launching its top-priority and unpublicized early-stage work program – GLP-1- for weight loss and diabetes control.

In the words of Mr. Bunka, this was a “high-risk program,” mainly because this class of drugs is considered “large molecules,” yet all of Lexaria’s previous investigations were concentrated on “small molecules.” However, by the end of November and early January 2024, the company reported positive interim and final human pilot study results using a single semaglutide dose of a Rybelsus(R) tablet to a matching dose from Rybelsus(R) that had been compound formulated in capsule form using DehydraTECH processing technology enhancements. This was a massive milestone for Lexaria, with Bunka describing the results as “surprising.” Of note was that DehydraTECH processing delivered a statistically-significant higher proportion of the semaglutide and did so more quickly, ultimately having a statistically-significant impact on blood sugar.

GLP-1 drugs have been receiving rising interest recently. Having received FDA approvals as recently as 2021 and 2022, mainly given its health benefits and potential market size, Lexaria understands that this could be the next best thing, hence its focus on this drug class.

“Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations,” noted Mr. Bunka.

“Given the overwhelming interest in the GLP-1 sector, this will be a main focus. We are not at this time planning additional 2024 research in the antiviral, nicotine, or PDE5 sectors. We have solid early-stage data in each of those areas that will allow us to build upon those at the right time,” he added.

Mr. Bunka has reiterated that 2024 will be the year that Lexaria’s hard work will prove its worth. He looks to follow up on the positive early-stage results achieved in 2023, even as it embarks on two human pilot studies, a multi-arm 12-week animal chronic study, a human chronic weight-loss and diabetes study, as well as a multi-month stability testing of DehydraTECH GLP-1. Mr. Bunka is confident that its focus on GLP-1 drugs will yield this outcome.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Operators Say Marijuana Incubators Could Boost Equity While Growing Business

A set of fresh marijuana incubators and mentorship initiatives now offer support and practical training to small-scale cannabis brands and newcomers, aiming to promote equity and create opportunities for individuals affected by the consequences of the drug war. In exchange, organizers anticipate gaining advantages from local community ties and affordable labor while also inspiring employees with purpose-driven tasks.

With the decline in available capital in the marijuana sector, most operators feel compelled to accomplish more with limited resources. Oscar Carrillo, who had served four years in prison for drug sales, found it discouraging that large multistate operators (MSOs) dominated the recreational cannabis industry in New Jersey when it first opened for business in 2022.

Carrillo eventually received a social-equity license, which he perceived as validation. However, he encountered new challenges. His venture, Magic Garden Botanicals, funded through his successful telecommunications enterprise, aimed for vertical integration. Yet, obtaining suitable real estate posed a significant obstacle.

Just when Carrillo’s intentions to purchase beachfront real estate in Penns Grove, New Jersey, failed, he met Cannabiz Incubator founder Alan Trzuskoski. Trzuskoski was seeking tenants from various segments of the marijuana supply chain for his new establishment in Bridgeton, New Jersey. Inspired by his experiences in the Silicon Valley tech industry, Trzuskoski currently operates Cannabiz Incubator as a landlord offering consulting services, intending to turn the operation into an accelerator model.

Recognizing real estate as a major obstacle for startups, Trzuskoski concentrated on obtaining property in Bridgeton, an area designated for impact, and obtained permission from the local government to house up to 15 companies at the Cannabiz Incubator location. He currently rents the space to 6 tenants. His ultimate goal is to create an ecosystem of more manageable, resource-constrained businesses that can take on the market leaders.Aspiring business owners and those who have previously engaged in the markets sometimes have close relationships with the community, which allows them to customize their services.

For example, Carrillo intends to take advantage of the popularity of outlet stores in New Jersey by providing low-cost cannabis items in nonbranded packaging in a dispensary designed to resemble one.

Elsewhere, Zenbarn Farms, based in Waterbury Center, Vermont, expanded its presence by acquiring various marijuana facilities from the departing Curaleaf Holdings, focusing on regenerative farming practices to align with local preferences. With funding from the Pennywise Foundation, the founders hope to grow their incubator program to offer extensive knowledge in the whole supply chain while highlighting reciprocal benefits through worker development programs. The new owners intend to use live soil and wildflowers planted around the greenhouse’s perimeter to broaden their regenerative farming practices to cater more to local interests as farmers.

Meanwhile, in Humboldt County, Cookies, a California marijuana brand that operates Cookies University, hosts five students every summer under strict social-equity criteria. The program, led by industry veterans such as Lindsey Renner, immerses students in all aspects of the supply chain during two months, providing an alternative to entrepreneurship for those more inclined towards employment in retail, manufacturing and cultivation.

After graduation, some students stay on to work with Cookies, while others land jobs at other cannabis companies. Others go back to their old markets or carry on with their activism in areas where marijuana is still illegal.

As more people access the kind of training that the likes of Cookies University offers, industry actors such as SNDL Inc. (NASDAQ: SNDL) could have a sizeable pool of well-trained job seekers to choose from.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Software Effective Solutions Corp. (SFWJ) Experts Work with Partners, Customers to Meet Impressive Market Growth

  • Research forecasts global medical marijuana space will see CAGR of 22.32% over the next decade
  • Several key factors contribute to double-digit growth
  • MedCana has assembled a team of pharmaceutical scientists who are some of the world’s most respected chemists

Recent forecasts for the global medical marijuana sector indicate significant growth, a trend that Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) is paying close attention to. A global infrastructure and holding company in the cannabis industry, MedCana is on a mission to become the world’s premier resource for pharmaceutical cannabis products.

The recent ResarchAndMarket.com article reported that the global medical marijuana market size was estimated to be $16.88 billion in 2023 and is expected to reach at $154.83 billion by 2034, with a CAGR of 22.32% during the 2024–2034 forecast period (https://cnw.fm/ON1OY). “Growing awareness regarding various therapeutic applications of the marijuana, a surge in permitting the usage of medical marijuana, increasing adoption of cannabis in therapeutic applications, rising research and development activities, growing prevalence of chronic diseases, and increase in acquisition of market players for the manufacturing of advanced medical products are some of the key factors boosting the market growth,” the article stated.

“The North America region is anticipated for the highest revenue share during the forecast period, owing to the surge in cannabis legalization and increasing product launches by major market players,” the article continued. “Increased launch of advanced medical products is predicted to boost the market growth during the forecast period. Medical marijuana, also known as medical cannabis, is a marijuana plant extract utilized to alleviate symptoms, illnesses, and various health conditions. Numerous North American states have relaxed laws regarding cannabis use, both for medical and recreational purposes.”

The article also noted that many other countries worldwide are following North America’s lead by legalizing cannabis. “The increasing trend of cannabis decriminalization is expected to significantly boost the development and launch of medical marijuana,” the report concluded.

With this backdrop of growing awareness and acceptance of medical cannabis, MedCana is well positioned to become an industry leader. The company has assembled a team of pharmaceutical scientists that are some of the most respected chemists in the world (https://cnw.fm/tPBhw). These experts work closely with MedCana partners and customers to create premium pharmaceutical-grade cannabis extracts that will meet the growing worldwide demand for high-quality products.

MedCana has established five companies focused on pharmaceutical cannabis production, as well as a software company focused on managing processes for plant-to-patient operations. In addition, the company recently rounded out its portfolio of holdings with the acquisition of an irrigation and greenhouse technology company.

The company’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts globally.

For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — New Study Explores How Cannabis Entourage Effect Impacts Therapeutic Benefits

A recent review that delves into the collaborative interplay of different marijuana chemical compounds, such as flavonoids, terpenes and cannabinoids, has shown that to fully understand the therapeutic potential of marijuana, it’s important to understand how the different constituents interact. Echoing sentiments expressed in the cannabis community for years, the study underscores that the effects of cannabis extend beyond only CBD and THC.

The study stresses the entourage effect, which describes the complex interactions between flavonoids, terpenes, cannabinoids and other chemicals found in marijuana plants. The study, published in the scientific journal “Molecules” last month, highlights the need to explore these complex connections to fully realize cannabis’ therapeutic potential in the field of natural plant medicine.

The study recommends a more thorough investigation of the precise ratios of flavonoids, terpenes and cannabinoids in various marijuana products or strains. It implies that this kind of examination can result in the creation of more specialized and efficient medical treatments.

Terpenes and cannabinoids interact with the body’s endocannabinoid system to produce a range of effects, including neuroprotective, anti-inflammatory and analgesic properties. However, research indicates that other substances in the plant may also have an impact on their effects, which may not be entirely attributable to their separate actions.

The research notes that terpenes, for instance, have demonstrated pharmacological properties and can interact with neurotransmitter receptors and enzymes, potentially modulating the effects of cannabinoids. Further, the entourage effect proposes that terpenes and cannabinoids working together could have a therapeutic benefit that is more potent than the sum of their separate actions.

The authors also cited studies that suggest that flavonoids may have neuroprotective, antioxidant, and anti-inflammatory qualities with cannflavins, a type of flavonoid, showing strong anti-inflammatory properties, especially against neuroinflammation. The study ALSO sheds light on the intricate network of chemical interactions that could influence the effects of cannabis on individuals.

However, the authors stress the need for further research to elucidate the underlying mechanisms and synergistic effects of flavonoids, terpenes and cannabinoids. They further highlight the importance of exploring the biotechnological, bioactivities and biosynthesis applications of these compounds to harness their potential and expand treatment options.

The study also notes that the regulatory obstacles to marijuana research present serious difficulties. It highlights how important it is to resolve these barriers, especially those resulting from marijuana’s Schedule I status, to enable more widespread access to marijuana products for research.

Companies such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) may be doing a lot behind the scenes to leverage the therapeutic effects of combining different components of marijuana plants.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

New England Cannabis Convention To Be Held In Boston, MA

Businesses, leaders, enthusiasts, and service providers of the cannabis spectrum are all invited to the NECANN Boston Convention, the 2nd largest B2B cannabis industry event across the globe. Since its 70th booth convention back in 2015, NECANN has come a long way. This year’s convention will feature over 350 exhibitors, several workshops, five full programming tracks, and a day-long financial/investor summit. The age limit to attend the conference is 18+ unless accompanied by a guardian.

The NECANN event is a phenomenal business platform attracting the New England cannabis trading community and other visitors. Influential cannabis industry leaders will be at the event, offering critical knowledge and developing industry insights. Experts will share strategies, ideas, and trends in the cannabis industry, while attendees harness the latest growth opportunities the platform offers. Enjoy unique experiences of networking and communication among peers, investors, and industry leaders.

Discussions will cover a number of important topics ranging from 280 changes and cannabis exit strategies, to insights from experts on sourcing diverse products, exploring funding through social equity programs, building a meaningful business network, and other subjects. Industry leaders will also explain the importance of community involvement, and how data analytics can impact business performance. In addition, the panel will talk about illicit cannabis operators based on recent numbers provided to them.

The NECANN  Boston Convention offers numerous business and growth avenues to the cannabis community. You will learn the latest industry trends and technologies to stay competitive in the fast-growing cannabis industry.

Due to popular demand, a THIRD exhibit hall, along with more programming and workshops, will be added.

To learn more, visit https://cnw.fm/5DLNO

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Teenage Brains More Susceptible to Cannabis Harm

Only 35% of 12- to-17-year-olds believe that smoking cannabis at least twice a week carries a major risk, according to the 2021 National Survey on Drug Use and Health (NSDUH). This low perception of risk among teenagers is concerning and is partly fueled by the widespread availability of marijuana, leading to the mistaken belief that it is entirely safe, states Beth Ebel, a pediatrician affiliated with Seattle Children’s Hospital and the University of Washington School of Medicine.

The main psychoactive ingredient in cannabis, THC, alters brain chemistry to produce a “high.” The THC may have unexpected consequences on the brain, especially in young people, according to Ebel, who highlights that these effects could result in addiction and psychosis as well as other long-term health problems.

Notably, THC concentrations in modern cannabis plants are far higher than in previous generations; the potency can reach 20% or more. Furthermore, THC levels in concentrated marijuana products such as shatter and wax can reach up to 95%, which makes them much more potent and worthy of their own classification, according to Yasmin Hurd, a neuroscientist at the Icahn School of Medicine at Mount Sinai.

The adolescent phase is especially precarious for marijuana use, given the ongoing development of the brain, notes Hurd. At this point, the brain experiences major changes, including the formation of new connections, the strengthening of preexisting ones and the pruning away of superfluous ones. THC, however, interferes with the endocannabinoid mechanism, which is essential for brain growth and other physiological processes, severely affecting this developing process. Research on growing brains — both in people and animals — shows that THC has deleterious effects that result in long-term deficits in learning and memory.

For instance, a 2019 study by Hurd and her team on THC-injected teenage rats revealed abnormal nerve cell connections in the prefrontal cortex, an area of the brain essential for emotional control and problem-solving. Similarly, teens’ prefrontal cortex thinning was shown to be accelerated in marijuana users’ MRI scans, a sign of aberrant brain development, according to a 2021 study.

In addition to impairing cognition, teenage cannabis use increases the likelihood of mental-health issues such as anxiety and sadness, according to a 2023 study. Notably, individuals with marijuana-use disorder are more prone to experiencing mental-health issues, with higher rates of depression and suicidal thoughts observed among adolescents who misuse marijuana.

Furthermore, the age at which marijuana use first occurs has a substantial impact on the risk of developing a marijuana use disorder, with adolescents showing a higher vulnerability than young adults.

Teenage cannabis usage frequently results from coping mechanisms for different stressors, including anxiety or sadness, highlighting the intricate relationship between substance abuse and mental health. Misuse of cannabis, however, can worsen symptoms related to mental health, creating a harmful cycle of greater usage and elevated anxiety.

Daily cannabis usage during adolescence is linked to negative effects in adulthood, including substance misuse, suicidal thoughts and reduced educational attainment, according to longitudinal research. Additionally, there is evidence linking marijuana addiction to the development of schizophrenia. Specifically, young boys are more likely to experience an association between marijuana use disorder and new occurrences of schizophrenia.

These concerns about the potential effects of cannabis on teenage brains illustrates why licensed cannabis companies such as Prime Harvest Inc. implement stringent age-verification systems so that only those of age can purchase products from their retail outlets.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ), Subsidiary Ink Multiyear Deal with Danziger Colombia

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) and its majority-controlled subsidiary, Eko2o Environmental Solutions S.A.S., have signed a multiyear contract with Danziger Colombia. According to the announcement, the agreement outlines plans for Colombia-based Eko2o, a leading provider of greenhouse infrastructure and agricultural technology, to provide greenhouse infrastructure services, irrigation products and technology to Danziger’s flower operations in Colombia. The company anticipates the agreement, which marks a pivotal moment for both organizations in their commitment to innovative agricultural practices, will result in between $2.5 million and $3 million in revenue over the next three years. Eko2o specializes in providing state-of-the-art greenhouse infrastructure and agricultural technology solutions and is focused on enhancing the efficiency and sustainability of agricultural production in Colombia and beyond. “We are thrilled to embark on this initial phase with Danziger,” said Eko2o S.A.S CEO Juan Ricardo Velez in the press release. “This partnership not only represents a significant milestone for our company but also sets the stage for future expansion. We eagerly anticipate further growth with Danziger in the near future and are confident that this agreement will pave the way for more collaborations with other leading flower and cannabis producers globally and nationally.”

To view the full press release, visit https://ccw.fm/CN3dM

ABOUT Software Effective Solutions

Software Effective Solutions/MedCana is a holding company focused on developing companies in the agricultural technology and the cannabis industries. As MedCana moves forward with its expansion plans, the company remains committed to delivering on its promise of building a solid foundation for future growth of its holdings. For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SWISF are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks off 2024 with FDA IND Submission for its HYPER-H23-1 Phase 1b Human Clinical Trial

  • Lexaria, a global innovator in drug delivery platforms, just announced the submission of its IND application with the FDA for its HYPER-H23-1 phase 1b hypertension clinical trial
  • This study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) technology, specifically DehydraTECH-CBD, in hypertensive patients
  • Lexaria expects to build on success of its previous studies, which showed positive results and DehydraTECH-CBD’s potential to have broad therapeutic utility

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced the submission of its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its HYPER-H23-1 phase 1b hypertension clinical trial. The submission follows a successful pre-IND meeting with the FDA, an integral step in the IND’s development and filing (https://cnw.fm/exwpC).

Titled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” this study will seek to evaluate the safety and tolerability of Lexaria’s patented DehydraTECH(TM) and specifically DehydraTECH-CBD in hypertensive patients. Secondary objectives will also include efficacy evaluation in reducing blood pressure and detailed pharmacokinetic testing.

The IND submission was initially set for the end of August 2023 but was delayed by the overdue delivery of required analytical and stability information from one of Lexaria’s core ingredient suppliers. However, the company has since made tremendous progress and looks to commence with its HYPER-H23-1 clinical trial as soon as possible following IND effectiveness, subject to certain conditions, including funding.

Lexaria is optimistic about the study and looks to build on the success of its previous studies that date back to 2018. So far, the company has sponsored five investigator-initiated human clinical studies of its DehydraTECH-CBD in an aggregate total of 134 people and has not recorded a single adverse event. Positive results from these studies included significant reductions in resting blood pressure over both acute and multi-week dosing regimens alone and, in some cases, complementary to standard-of-care medications. These results suggested that DehydraTECH-CBD has the potential to have broad therapeutic utility, and that is something Lexaria is looking to explore more in its HYPER-H23-1 clinical study.

This submission affirms Lexaria’s commitment to creating shareholder value. It also points to its goal to fulfill the promises made to its shareholders, as detailed in its roadmap for the 2024 calendar year. For Chris Bunka, Lexaria’s CEO, this marks a significant milestone in line with his pledge to do all he can to “turn 2024 into the year that Lexaria leaps forward.”

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN